TABLE 1.
Patient characteristics
| N (%) | |
|---|---|
| Number of patients | 33 |
| Age (years) median (range) | 38 (22–66) |
| Sex | |
| Male | 22 (66.7) |
| Female | 11 (33.3) |
| Performance status acc. to Karnofsky (%) | |
| 60 | 1 (3.1) |
| 70 | 3 (9.1) |
| 80 | 11 (33.3) |
| 90 | 14 (42.4) |
| 100 | 4 (12.1) |
| Oedema | |
| ≤ 1 cm | 11 (33.3) |
| > 1 cm | 19 (57.6) |
| n.e. | 3 (9.1) |
| History of glioblastoma | |
| Primary glioblastoma | 31 (93.9) |
| Secondary glioblastoma | 2 (6.1) |
| Localisation of the tumour | |
| Frontal | 12 (36.4) |
| Parietal | 4 (12.1) |
| Trigonal | 2 (6.1) |
| Temporal | 8 (24.2) |
| Occipital | 1 (3.0) |
| Frontoparietal | 1 (3.0) |
| Insula | 1 (3.0) |
| Parietooccipital | 2 (6.1) |
| Thalamus | 2 (6.1) |
| Side of tumour localisation | |
| Right | 10 (30.3) |
| Left | 22 (66.7) |
| Bilateral | 1 (3) |
| Extent of resection | |
| Biopsy | 4 (12.1) |
| Subtotal | 10 (30.3) |
| Total | 19 (57.6) |
| Cognitive impairment | |
| Yes | 11 (33.3) |
| No | 22 (66.7) |
| Stroke | |
| Yes | 2 (6.1) |
| No | 31 (93.9) |
| Initial chemotherapy | |
| Temozolomide | 6/33 (18.2%) |
| CCNU | 15/33 (45.5%) |
| Fotemustine/Dacarbacine | 12/33 (36.4%) |
N = numbers, n.e. = not evaluable